Evidence map›Paper›PMID 22966167›Full record

ArticleBlood2012

Mesenchymal stem cells are injured by complement after their contact with serum.

Yan Li, Feng Lin

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 95 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
95citing papers in PubMed, 1 pooled it
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

95 citing papers in PubMed, 1 synthesis or guideline pooled it, 182 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article

35 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 2 countries.

Yan LiDepartment of Pathology, Case Western Reserve University, Cleveland, OH, USA.
Feng Lin
State Key Laboratory of Biotherapy

Funding

Local inhibition of complement to improve MSC-based therapy for diabetesR01DK103581 · NIDDK · CLEVELAND CLINIC LERNER COM-CWRU · PI HAMILTON, THOMAS A., LIN, FENG C · 2015 to 2018
$1.4M
Synergy between T cells and Complement in EAER01NS052471 · NINDS · CASE WESTERN RESERVE UNIVERSITY · PI LIN, FENG C · 2005 to 2010
$1.3M
NIDDK NIH HHS R01 DK103581NINDS NIH HHS R01 NS052471NINDS NIH HHS R01NS052471
6 · The paper itself

Abstract

Despite the potent immunosuppressive activity that mesenchymal stem cells (MSCs) display in vitro, recent clinical trial results are disappointing, suggesting that MSC viability and/or function are greatly reduced after infusion. In this report, we demonstrated that human MSCs activated complement of the innate immunity after their contact with serum. Although all 3 known intrinsic cell-surface complement regulators were present on MSCs, activated complement overwhelmed the protection of these regulators and resulted in MSCs cytotoxicity and dysfunction. In addition, autologous MSCs suffered less cellular injury than allogeneic MSCs after contacting serum. All 3 complement activation pathways were involved in generating the membrane attack complex to directly injure MSCs. Supplementing an exogenous complement inhibitor, or up-regulating MSC expression levels of CD55, one of the cell-surface complement regulators, helped to reduce the serum-induced MSC cytotoxicity. Finally, adoptively transferred MSCs in complement deficient mice or complement-depleted mice showed reduced cellular injury in vivo compared with those in wild type mice. These results indicate that complement is integrally involved in recognizing and injuring MSCs after their infusion, suggesting that autologous MSCs may have ad-vantages over allogeneic MSCs, and that inhibiting complement activation could be a novel strategy to improve existing MSC-based therapies.

Indexed as

Mesenchymal Stem Cell TransplantationAdoptive TransferAnimalsCD55 AntigensComplement ActivationComplement Inactivating AgentsComplement System ProteinsHumansImmunity, InnateImmunoglobulin GImmunomodulationMesenchymal Stem CellsMicePrimary Cell CultureSerumTransplantation, AutologousCD55 AntigensComplement Inactivating AgentsComplement System ProteinsImmunoglobulin G

Identifiers

PMID22966167
PMCPMC3482856
OpenAlexW2010526570

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.